BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 33785763)

  • 1. Development of a novel transcription factors-related prognostic signature for serous ovarian cancer.
    Li H; Wu N; Liu ZY; Chen YC; Cheng Q; Wang J
    Sci Rep; 2021 Mar; 11(1):7207. PubMed ID: 33785763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning-assisted analysis of epithelial mesenchymal transition pathway for prognostic stratification and immune infiltration assessment in ovarian cancer.
    Li Q; Xiao X; Feng J; Yan R; Xi J
    Front Endocrinol (Lausanne); 2023; 14():1196094. PubMed ID: 37404304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a multi-gene-based immune prognostic signature in ovarian Cancer.
    Cao T; Shen H
    J Ovarian Res; 2021 Jan; 14(1):20. PubMed ID: 33509250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of immunity- and ferroptosis-related genes for predicting the prognosis of serous ovarian cancer.
    Yuan X; Zhou Q; Zhang F; Zheng W; Liu H; Chen A; Tao Y
    Gene; 2022 Sep; 838():146701. PubMed ID: 35777713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database.
    Liu J; Xu W; Li S; Sun R; Cheng W
    Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439
    [No Abstract]   [Full Text] [Related]  

  • 6. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
    Jiao J; Jiang L; Luo Y
    Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and validation of a transcription factors-based prognostic signature for ovarian cancer.
    Cheng Q; Li L; Yu M
    J Ovarian Res; 2022 Feb; 15(1):29. PubMed ID: 35227285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a five-gene signature as a novel prognostic marker in ovarian cancer.
    Wang R; Ye XH; Zhao XL; Liu JL; Zhang CY
    Neoplasma; 2019 May; 66(3):343-349. PubMed ID: 30569721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and verification of a ten-gene signature predicting overall survival for ovarian cancer.
    Liu J; Xu F; Cheng W; Gao L
    Exp Cell Res; 2020 Oct; 395(2):112235. PubMed ID: 32805252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying the Role of Oxidative Stress-Related Genes as Prognostic Biomarkers and Predicting the Response of Immunotherapy and Chemotherapy in Ovarian Cancer.
    Liu Q; Yang X; Yin Y; Zhang H; Yin F; Guo P; Zhang X; Sun C; Li S; Han Y; Yang Z
    Oxid Med Cell Longev; 2022; 2022():6575534. PubMed ID: 36561981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four Types of RNA Modification Writer-Related lncRNAs Are Effective Predictors of Prognosis and Immunotherapy Response in Serous Ovarian Carcinoma.
    Ye L; Pan K; Fang S; Wu SN; Chen S; Tang S; Wang N; Zhang H; Tong X; Shi X; Feng S; Xiang D; Zou R; Hu Y; Xue X; Guo G
    Front Immunol; 2022; 13():863484. PubMed ID: 35585970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and Clinical Significance of Microtubule-Actin Cross-Linking Factor 1 in Serous Ovarian Cancer.
    Liu L; Hu K; Zeng Z; Xu C; Lv J; Lin Z; Wen B
    Recent Pat Anticancer Drug Discov; 2021; 16(1):66-72. PubMed ID: 33573562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
    Yang M; Xie X; Ding Y
    Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of epigenetic genes for predicting prognosis and immunotherapy response of ovarian cancer.
    Shen W; Jiang W; Ye S; Sun M; Yang H; Shan B
    Jpn J Clin Oncol; 2022 Jul; 52(7):742-751. PubMed ID: 35435215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel risk score system for assessment of ovarian cancer based on co-expression network analysis and expression level of five lncRNAs.
    Zhao Q; Fan C
    BMC Med Genet; 2019 Jun; 20(1):103. PubMed ID: 31182053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Comprehensive Analysis of Interferon-Related Prognostic Signature with regard to Immune Features in Ovarian Cancer.
    An Y; Duan H
    Dis Markers; 2022; 2022():7900785. PubMed ID: 35769811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.